New stock news | Micotan once again submits application to Hong Kong Stock Exchange
According to the disclosure on March 11th by the Hong Kong Stock Exchange, Shenzhen Maiketian Biomedical Technology Co., Ltd. has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International acting as joint sponsors.
According to the disclosure on March 11 by the Hong Kong Stock Exchange, Shenzhen Maiketen Biomedical Technology Co., Ltd. (referred to as Maiketen) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International as joint sponsors. The company had submitted its prospectus to the Hong Kong Stock Exchange on September 11, 2025. The prospectus shows that Maiketen is a global medical device provider that meets the clinical needs of a wide range of clinical departments, wards, clinics in medical institutions, community health centers, laboratories, and home care settings. As of December 31, 2025, the company's product portfolio includes over 60 life support products, 110 minimally invasive interventional products, and 160 in vitro diagnostic products.
Related Articles
GENSCRIPT BIO (01548) releases annual financial results, with a net loss attributable to shareholders of 533 million USD, a year-on-year shift from profit to loss.
SINOPEC SEG (02386) releases annual results, with shareholders' profit of 1.798 billion yuan, a year-on-year decrease of 27.1%.
CITIC SEC: The impact of rising PET prices is controllable, and beverage companies are expected to reduce hedging costs.
GENSCRIPT BIO (01548) releases annual financial results, with a net loss attributable to shareholders of 533 million USD, a year-on-year shift from profit to loss.
SINOPEC SEG (02386) releases annual results, with shareholders' profit of 1.798 billion yuan, a year-on-year decrease of 27.1%.
CITIC SEC: The impact of rising PET prices is controllable, and beverage companies are expected to reduce hedging costs.
